Antibody Isotype Families
Clinically relevant antibodies in various Ig isotypes
Monoclonal antibodies (mAbs) have become a major tool in cancer therapy. They function through various mechanisms with the ultimate effect of priming either the innate or adaptive arm of the immune system to target tumor cells for destruction.
The efficacy of antibodies is governed by their bifunctional nature: the variable region confers antigen specificiy and the constant region triggers antibody-mediated effector functions by engaging a variety of Fc receptors.
These effector functions include complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
One approach employed to enhance the efficacy of therapeutic antibodies is to modify the immunoglobulin (Ig) constant region.
|Effector functions||Native human isotypes||Engineered human isotypes||Native mouse isotypes|
InvivoGen provides a series of clinically relevant antibodies, such as anti-hCD20 (rituximab, ofatumumab, obinutuzumab), anti-HER2 (trastuzumab) and anti-hPD1 (nivolumab, pembrolizumab), available in their original format or with different Ig isotypes, either native or engineered, thus constituting an antibody isotype family (3 different isotypes) or collection (up to 14 different isotypes).
These antibody isotype families or collections will help you study the effector functions between different isotypes and determine which isotype is the most suitable for your application.
InvivoGen’s clinically relevant antibodies are generated by recombinant DNA technology, produced in CHO cells and purified by affinity chromatography.
They are validated by flow cytometry, are sterile and contain no sodium azide. All of these antibodies feature the human (or murine) kappa light chain.
Large quantities are available upon request.